Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Oncolytic Viruses as Cancer Therapeutics
share announcement

Oncolytic Viruses as Cancer Therapeutics

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".

Deadline for manuscript submissions: closed (31 March 2022) | Viewed by 6880

Special Issue Editors

Dr. Mariangela Garofalo

E-Mail Website
Guest Editor
Department of Pharmaceutical and Pharmacological Sciences, University of Padua, 35131 Padova, Italy
Interests: oncolytic adenoviruses; extracellular vesicles; cancer therapy; immunotherapy; drug delivery
Dr. Lukasz Kuryk

E-Mail
Guest Editor
Department of Virology, National Institute of Public Health–National Institute of Hygiene, Warsaw, Poland
Interests: oncolytic virotherapy; oncolytic adenovirus; cancer; immunotherapy; immuno-oncology; animal models; clinical studies in immuno-oncology

Special Issue Information

Dear Colleagues,

The concept of using viruses to treat cancer dates back over a century. In the last two decades, tremendous advances have been made in this field—of particular note, talimogene laherparepvec (T-VEC), back in 2015, became the first FDA-approved oncolytic adenovirus (OV) for the treatment of advanced melanoma. Nevertheless, despite these advances, the majority of cancer patients respond poorly, thus indicating the need for novel approaches that are able to tackle the demanding aspects of cancer. In this scenario, novel OVs can produce selective tumor cell kill targets and can be genetically manipulated to induce anti-tumor immune responses, especially in combination with immunotherapies, resulting in better clinical outcomes than monotherapies alone. Pharmaceutics is now seeking original papers, communication and review articles that describe the design, optimization, delivery strategies and application of innovative combination therapies to enhance cancer immunotherapy.

Dr. Mariangela Garofalo
Dr. Lukasz Kuryk
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • oncolytic adenoviruses
  • immunotherapy
  • cancer treatment
  • cancer immunotherapy
  • cancer vaccine

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

22 pages, 7373 KiB  
Article
Combination Therapy of Novel Oncolytic Adenovirus with Anti-PD1 Resulted in Enhanced Anti-Cancer Effect in Syngeneic Immunocompetent Melanoma Mouse Model
by Mariangela Garofalo, Laura Bertinato, Monika Staniszewska, Magdalena Wieczorek, Stefano Salmaso, Silke Schrom, Beate Rinner, Katarzyna Wanda Pancer and Lukasz Kuryk
Pharmaceutics 2021, 13(4), 547; https://doi.org/10.3390/pharmaceutics13040547 - 14 Apr 2021
Cited by 11 | Viewed by 3009
Abstract
Malignant melanoma, an aggressive form of skin cancer, has a low five-year survival rate in patients with advanced disease. Immunotherapy represents a promising approach to improve survival rates among patients at advanced stage. Herein, the aim of the study was to design and [...] Read more.
Malignant melanoma, an aggressive form of skin cancer, has a low five-year survival rate in patients with advanced disease. Immunotherapy represents a promising approach to improve survival rates among patients at advanced stage. Herein, the aim of the study was to design and produce, by using engineering tools, a novel oncolytic adenovirus AdV-D24- inducible co-stimulator ligand (ICOSL)-CD40L expressing potent co-stimulatory molecules enhancing clinical efficacy through the modulation of anti-cancer immune responses. Firstly, we demonstrated the vector’s identity and genetic stability by restriction enzyme assay and sequencing, then, by performing in vitro and in vivo pre-clinical studies we explored the anti-cancer efficacy of the virus alone or in combination with anti PD-1 inhibitor in human melanoma cell lines, i.e., MUG Mel-1 and MUG Mel-2, and in immunocompetent C57BL/6 melanoma B16V mouse model. We showed that both monotherapy and combination approaches exhibit enhanced anti-cancer ability and immunogenic cell death in in vitro settings. Furthermore, AdV-D24-ICOSL-CD40L combined with anti PD-1 revealed a fall in tumor volume and 100% survival in in vivo context, thus suggesting enhanced efficacy and survival via complementary anti-cancer properties of those agents in melanoma therapy. Collectively, the novel oncolytic vector AdV-D24-ICOSL-CD40L alone or in combination with anticancer drugs, such as check point inhibitors, may open novel therapeutic perspectives for the treatment of melanoma. Full article
(This article belongs to the Special Issue Oncolytic Viruses as Cancer Therapeutics)
►▼ Show Figures

Figure 1

Review

Jump to: Research

11 pages, 724 KiB  
Review
Giving Oncolytic Viruses a Free Ride: Carrier Cells for Oncolytic Virotherapy
by Alberto Reale, Arianna Calistri and Jennifer Altomonte
Pharmaceutics 2021, 13(12), 2192; https://doi.org/10.3390/pharmaceutics13122192 - 18 Dec 2021
Cited by 17 | Viewed by 3113
Abstract
Oncolytic viruses (OVs) are an emerging class of therapeutics which combine multiple mechanisms of action, including direct cancer cell-killing, immunotherapy and gene therapy. A growing number of clinical trials have indicated that OVs have an excellent safety profile and provide some degree of [...] Read more.
Oncolytic viruses (OVs) are an emerging class of therapeutics which combine multiple mechanisms of action, including direct cancer cell-killing, immunotherapy and gene therapy. A growing number of clinical trials have indicated that OVs have an excellent safety profile and provide some degree of efficacy, but to date only a single OV drug, HSV-1 talimogene laherparepvec (T-Vec), has achieved marketing approval in the US and Europe. An important issue to consider in order to accelerate the clinical advancement of OV agents is the development of an effective delivery system. Currently, the most commonly employed OV delivery route is intratumoral; however, to target metastatic diseases and tumors that cannot be directly accessed, it is of great interest to develop effective approaches for the systemic delivery of OVs, such as the use of carrier cells. In general, the ideal carrier cell should have a tropism towards the tumor microenvironment (TME), and it must be susceptible to OV infection but remain viable long enough to allow migration and finally release of the OV within the tumor bed. Mesenchymal stem cells (MSCs) have been heavily investigated as carrier cells due to their inherent tumor tropism, in spite of some disadvantages in biodistribution. This review focuses on the other promising candidate carrier cells under development and discusses their interaction with specific OVs and future research lines. Full article
(This article belongs to the Special Issue Oncolytic Viruses as Cancer Therapeutics)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop